根据《上市公司股份回购规则》（2025年修订）、《上海证券交易所上市公司自律监管指引第7号一一 回购股份》（2025年3月修订）等相关规定，现将公司首次回购股份情况公告如下： 2025年12月3日，公司通过上海证券交易所交易系统以集中竞价交易方式首次回购公司股份111,121股， 占公司总股本407,807,559股的比例为0.03%，回购成交的最高价为27元/股，最低价为26.8元/股，支付的 资金总额为人民币2,990,977.1元（不含交易费用）。本次回购股份符合法律法规及公司回购股份方案的 规定。 三、其他事项 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 2025年10月30日，深圳微芯生物科技股份有限公司（以下简称"公司"）召开第三届董事会第十七次会 议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》。同意公司使用不低于人民币 1,000万元（含），不超过人民币1,500万元（含）的自有资金和股份回购专项贷款 ...

Core Viewpoint - The approval of two supplemental new drug applications for Selinexor (希维奥) by the Hong Kong Department of Health marks a significant expansion for the company in the Hong Kong market, enhancing its competitiveness in the biopharmaceutical industry [1] Group 1: Company Developments - The stock price of Dechra Pharmaceuticals-B (德琪医药-B) increased by approximately 6%, reaching HKD 4.34, with a trading volume of HKD 9.4944 million [1] - The approved applications are for the treatment of multiple myeloma (in combination with bortezomib and dexamethasone for adult patients who have received at least one prior therapy) and relapsed or refractory diffuse large B-cell lymphoma (as a monotherapy for adults who have undergone at least two lines of systemic therapy and are not eligible for hematopoietic stem cell transplantation) [1] Group 2: Industry Implications - The approval signifies the company's ongoing enhancement in research and market promotion capabilities within the biopharmaceutical sector [1] - The introduction of Selinexor is expected to meet the treatment needs for relevant diseases in the Hong Kong market, thereby improving the company's competitive position in the biotechnology industry [1]

近日，圣湘生物举办第三季度业绩说明会，在回答投资者关注的基因测序仪项目相关进展时，圣湘生物 董事长、总经理戴立忠表示，在基因测序领域，公司技术平台取得进一步突破，SansureSeq1000（高通 量）、FASTASeq300Dx（桌面级）及FASTASeqS（快速版）三款测序仪形成了较为完整的产品矩阵， 构建了"仪器+试剂+数据"的一体化布局。同时，创新推出的一步法呼吸道病原靶向基因检测、生殖道 病原微生物靶向基因检测、泛感染靶向基因检测等产品已广泛辐射全国多家客户，公司前三季度测序业 务实现同比增长约150%，展现出强劲的增长势头。 戴立忠提到，今年以来，公司拟参与设立常州灵仲创业投资合伙企业、湖南金芙蓉圣湘生物基金等，将 投资于包括AI医疗应用领域及创新药械等医疗行业技术领先、潜在市场空间大的企业。圣维荣泉、维 特力新等基金合伙人均为具有多年投资专业经验、丰富行业资源、成熟管理模式的专业投资机构，借助 其资本市场资源、管理经验和平台优势，结合圣湘生物在行业内多年的专业知识和产业经验，可有效整 合各方优势资源，进一步探索产业与资本赋能良性互动的多元化发展模式，打造共创、共进、共享、共 赢的行业新生态。 此 ...

Core Viewpoint - Morgan Stanley's 2026 outlook for China's economy and stock market indicates a significant shift in global investors' perception, moving from a market lacking clear growth potential to one rich in growth opportunities, particularly in sectors like AI, new consumption, automation, and biotechnology [1][2]. Group 1: Foreign Investment Trends - Foreign investment sentiment towards the Chinese market is improving, with expectations for continued inflows in 2026 following a substantial valuation recovery in 2025 [2]. - The MSCI China Index has shown significant valuation recovery, marking a milestone for A-shares and Hong Kong stocks, leading to a renewed interest from global investors [2]. - Passive funds have seen a notable increase in inflows, while active funds remain cautious, with less than 5% of their global investment capacity allocated to Chinese stocks [3]. Group 2: Positive Economic Changes - Three positive changes in the Chinese economy have emerged since the "9·24" policy shift: 1. Enhanced policy responsiveness, with a focus on development and flexible adjustments [4]. 2. Resilience and innovation among Chinese enterprises, showcasing advancements in AI, smart vehicles, and biopharmaceuticals [4]. 3. A shift in global investor focus from dollar assets to diversified allocations, with a growing interest in China's tech innovations [4]. Group 3: Policy and Infrastructure Investment - The 2026 fiscal policy is expected to prioritize infrastructure investments in new areas such as underground pipeline renovations and green transition projects, driven by carbon reduction goals [5]. - Increased support for consumption through measures like birth subsidies and social security enhancements reflects a flexible and rich policy toolbox [5]. Group 4: Market Dynamics and Investment Strategy - The market's driving logic is set to change in 2026, with a completed valuation recovery and a stable, reasonable valuation level that can attract new capital [7]. - The anticipated easing of global liquidity, including three expected interest rate cuts by the Federal Reserve in the first half of 2026, will support stock assets [7]. - Investment strategies should focus on high-growth sectors aligned with China's long-term development, such as high-end manufacturing, AI, and biotechnology, while also including quality dividend-paying sectors like insurance [7].

以下文章来源于赛业生物订阅号 ，作者小赛 赛业生物订阅号 . 分享生命科学领域的前沿资讯、解读行业动态、讲解实用的学科知识、实验方法和技巧。 师姐 你的flox鼠和Cre鼠是同一个品系吗？实验后期很容易出现好几代交配完，才发现背 景不纯、Cre还泄露了的情况。 类似的对话，也许时常出现在你的身边，从课题启动到获得可靠数据，基因敲入模型的构建之路往往布满荆 棘： ❓ 传统ES打靶结合多代育种流程漫长，如何将模型交付周期缩短一半以上？ 如此种种，让宝贵的科研时间在反复验证中悄然流逝。 新一期线上课程 「基因敲入（KI）模型构建策略及应用案例分析」 将深入剖析。 课程时间： 12月9日（周二）晚7点 讲师： 赛业生物生产中心ES部经理李晓亮、生产中心分子部门经理王康 师妹 完蛋，我的敲入小鼠和预期的表型对不上，但我明明是按Protocol做的…… 通过这节课你可以学到什么？ ❓ 如何避免Cre工具鼠的泄露表达、重组效率低等问题对表型数据造成干扰？ ❓ 面对复杂条件性模型，如何在保证高成功率的同时，有效控制项目成本？ 1 KI、CKI模型分别对应的设计逻辑、适用场景及其在基因功能研究中的价值 2 新一代ES打靶技术如 ...

Group 1 - The Hong Kong stock market opened slightly higher on December 4, with the Hang Seng Index rising by 0.17% and the Hang Seng Biotechnology Index increasing by over 1% [1] - The Hong Kong Stock Connect Technology ETF (513860) saw a gain of 0.14%, with notable increases in constituent stocks such as Kingsoft Biotechnology and CanSino Biologics, both rising nearly 4% [1] - As of December 3, the Hong Kong Stock Connect Technology ETF (513860) attracted a total of 410 million yuan over the past nine trading days, with a net inflow of 74.36 million yuan on December 2 [1] Group 2 - Guosen Securities emphasizes that AI will remain a key focus through 2026, driven by the need for accelerated domestic hardware production and the expectation of more AI applications being implemented [2] - The Hong Kong Stock Connect Technology ETF (513860) closely tracks the CSI Hong Kong Stock Connect Technology Index, which selects 50 large-cap, high R&D investment, and fast-growing technology companies as sample stocks [2] - The top ten weighted stocks in the index include major players such as Alibaba-W, Tencent Holdings, SMIC, BYD Company, and Xiaomi Group-W [2]

Core Insights - The recent strategic investment by Yan Jianya, the new richest person in Shaanxi, involves acquiring an 8% stake in the A-share integrated marketing service provider Sanrenxing for a total of 450 million yuan, making him the second-largest shareholder after the controlling shareholder [2][4] - This investment is part of Yan's broader strategy to create a synergistic capital matrix across various sectors, including biotechnology, aerospace, and consumer goods [2][6] Investment Background - Yan Jianya's investment in Sanrenxing follows a previous collaboration where his firm, Sanyuan Capital, established a 220 million yuan industry fund with Sanrenxing in 2022, demonstrating a deepening relationship [4] - The partnership has been mutually beneficial, with Sanrenxing previously generating over 15 million yuan in profit from selling shares of its core client, Juzhi Biotechnology, which is also controlled by Yan [4][6] Company Performance - Sanrenxing is currently undergoing a performance adjustment, with revenue projected to decline from 5.653 billion yuan in 2022 to 4.208 billion yuan in 2024, and net profit dropping from 736 million yuan to 123 million yuan during the same period [4][5] - Despite these challenges, Yan's entry is seen as a potential catalyst for transformation, as Sanrenxing is exploring AI-driven marketing solutions and has made progress in new business areas such as computing services and sports lottery [4][6] Strategic Implications - Yan's investment is viewed as a critical move to enhance Sanrenxing's marketing capabilities, which are essential for the brand upgrade of Juzhi Biotechnology and the market promotion of aerospace products [6][7] - The integration of Yan's industrial resources with Sanrenxing's marketing expertise is expected to create a self-reinforcing ecosystem, facilitating resource sharing and mutual empowerment across different sectors [6][7] Future Outlook - As the commercial aerospace industry in Shaanxi approaches a trillion yuan in output, Yan's capital layout aligns with emerging trends in digital economy and new productivity [7] - The 450 million yuan investment in Sanrenxing is not just a strategic investment in a single company but represents a significant step in Yan's transition from industry chain layout to ecological operation [7]

最新ADP就业数据显示劳动力市场萎缩，使投资者增大了对美联储将于下周降息的押注。 有分析认为，生物医药行业对利率较为敏感，降息有利于中小生物医药公司降低融资成本，同时低息资 金增加研发管线。 受盘面影响，标普生物科技ETF、纳指生物科技ETF涨超2%。 | 代码 | 类型 名称 | 现价 | 涨跌 | 涨跌幅 ▼ | | --- | --- | --- | --- | --- | | 159502 | 跨 标普生物科技ETF T+0 | 1.337 | 0.039 | 3.00% | | 513290 | 跨 纳指生物科技ETF T+0 | 1.634 | 0.039 | 2.45% | 美股周三收高，纳斯达克生技股指数大涨1.96%。 ...

Core Viewpoint - Hansa Biopharma is undergoing a listing hearing on the Hong Kong Stock Exchange, with ICBC International as its sole sponsor, focusing on its proprietary technologies in structural biology, translational medicine, and clinical development [1] Product Pipeline - The company has developed a product pipeline that includes one core product and nine other candidates, targeting oncology and autoimmune markets [1] - The core product, HX009, is a self-developed anti-PD-1/SIRPα dual-function antibody fusion protein, which has completed Phase I clinical trials in Australia and China [1] - HX009 is currently involved in Phase Ib/I/IIa clinical projects in China for advanced melanoma, relapsed/refractory EBV-positive non-Hodgkin lymphoma, and advanced biliary tract cancer [1] - A combination study of HX009 with trastuzumab for advanced triple-negative breast cancer has been approved by the National Medical Products Administration, with the first patient recruitment expected to be completed by 2026 [1] Additional Clinical Products - The company also has two major clinical-stage products: HX301, a multi-target kinase inhibitor currently in Phase II studies for glioblastoma [1] - HX044, a novel dual-function anti-CTLA-4 antibody SIRPα fusion protein, is undergoing Phase I/IIa studies for advanced solid tumors [1]

科技日报北京12月3日电 （记者张佳欣）每一秒，都有数以万亿计的微小"包裹"在人的血液中穿 行，在体内细胞之间传递重要信息。这些被科学家称为"分子信使"的微粒，实际上是细胞外囊泡。如 今，澳大利亚贝克心脏与糖尿病研究所研究团队首次绘制出了细胞外囊泡的完整分子组分，并以前所未 有的细致程度呈现了信使携带的内容。相关论文发表于最新一期《自然细胞生物学》杂志。 为了让更多人能够了解这一发现，研究团队还开发了名为EVMap的互动式在线资源，免费向全球 科研人员开放。该平台整合了细胞外囊泡的完整分子组分信息，可用于样本比对、机制研究和潜在临床 标志物开发，或将显著提升相关研究的效率。 几十年来，科学界一直试图解析这些纳米级微粒的组成，但血液本身结构复杂，含有大量胆固醇、 抗体和其他纳米颗粒，导致在实验中难以将细胞外囊泡准确分离出来。由于缺乏对细胞外囊泡结构成分 的完整认识，科学家始终无法真正理解它们在体内承担的信息传递功能。 在最新研究中，团队利用超纯分离技术结合多组学分析，对健康人群血浆中的细胞外囊泡进行了系 统解析，最终识别出构成细胞外囊泡核心结构的182种蛋白质和52种脂类。他们还找到了另一组能够将 细胞外囊泡与 ...